Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 4/2016

01-08-2016 | Case Report

Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom

Authors: Tetsuo Kon, Naoki Nakagawa, Fumitsugu Yoshikawa, Kazunao Haba, Nagako Kitagawa, Michihiro Izumi, Setsuo Kumazaki, Satoshi Ishida, Ryuichi Aikawa

Published in: Clinical Journal of Gastroenterology | Issue 4/2016

Login to get access

Abstract

Immunoglobulin light-chain (AL) amyloidosis is characterized by the deposition of insoluble fibrils composed of immunoglobulin light chains secreted by monoclonal plasma cells. Given the recent advances in the therapy of AL amyloidosis, it is important to diagnose this disease as early as possible. Herein, we describe the case of a 62-year-old man with hepatitis C virus (HCV)-related cirrhosis presenting with hematochezia. Colonoscopy showed multiple submucosal hematomas within the region ranging from the transverse colon to the sigmoid colon. Kappa immunoglobulin light-chain amyloid deposition was also detected. Bone marrow examination revealed a monoclonal abnormal plasma cell population. Thus, the patient was diagnosed with systemic immunoglobulin light-chain amyloidosis. The hematochezia was conservatively managed. However, because of liver failure caused by liver cirrhosis, the patient developed massive pleural effusion and died of respiratory failure. Postmortem examination revealed amyloid deposition in the esophagus, stomach, duodenum, ileum, descending colon, pancreas, heart, and lung. In these organs, amyloid deposition was limited to the vascular wall. We concluded that AL amyloidosis can present hematochezia arising from submucosal hematoma in the large colon before other systemic symptoms appear.
Literature
1.
go back to reference Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012;26:137–54.CrossRefPubMed Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012;26:137–54.CrossRefPubMed
3.
go back to reference Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematol Am Soc Hematol Educ Program. 2010;2010:287–94. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematol Am Soc Hematol Educ Program. 2010;2010:287–94.
5.
6.
go back to reference Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med. 2014;53:403–12.CrossRefPubMed Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med. 2014;53:403–12.CrossRefPubMed
7.
go back to reference Huang X, Wang Q, Jiang S, et al. The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J. 2015;8:120–6.CrossRefPubMed Huang X, Wang Q, Jiang S, et al. The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J. 2015;8:120–6.CrossRefPubMed
8.
go back to reference James DG, Zuckerman GR, Sayuk GS, et al. Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol. 2007;5:582–8.CrossRefPubMed James DG, Zuckerman GR, Sayuk GS, et al. Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol. 2007;5:582–8.CrossRefPubMed
9.
go back to reference Klatt EC. Robbins and cotran atlas of pathology. 2nd ed. United States: Saunders; 2009. Klatt EC. Robbins and cotran atlas of pathology. 2nd ed. United States: Saunders; 2009.
10.
go back to reference Mumford A, O’Donnell J. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110:454–60.CrossRefPubMed Mumford A, O’Donnell J. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110:454–60.CrossRefPubMed
11.
go back to reference Thompson CA, Kyle R, Gertz M, et al. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010;85:171–3.PubMedPubMedCentral Thompson CA, Kyle R, Gertz M, et al. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010;85:171–3.PubMedPubMedCentral
12.
go back to reference Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97:1885–7.CrossRefPubMed Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97:1885–7.CrossRefPubMed
13.
go back to reference Spier BJ, Einstein M, Johnson EA, et al. Amyloidosis presenting as lower gastrointestinal hemorrhage. WMJ. 2008;107:40–3.PubMed Spier BJ, Einstein M, Johnson EA, et al. Amyloidosis presenting as lower gastrointestinal hemorrhage. WMJ. 2008;107:40–3.PubMed
14.
go back to reference Kim S-Y, Moon S-B, Lee SK, et al. Light-chain amyloidosis presenting with rapidly progressive submucosal hemorrhage of the stomach. Asian J Surg. 2016;39:113–5.CrossRefPubMed Kim S-Y, Moon S-B, Lee SK, et al. Light-chain amyloidosis presenting with rapidly progressive submucosal hemorrhage of the stomach. Asian J Surg. 2016;39:113–5.CrossRefPubMed
15.
go back to reference Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24:343–50.CrossRefPubMed Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24:343–50.CrossRefPubMed
16.
go back to reference Yildiz R, Yildirim B, Karincaoglu M, et al. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol. 2005;20:1115–20.CrossRefPubMed Yildiz R, Yildirim B, Karincaoglu M, et al. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol. 2005;20:1115–20.CrossRefPubMed
17.
go back to reference Barbosa M, Guardado J, Marinho C, et al. Cirrhotic cardiomyopathy: isn’t stress evaluation always required for the diagnosis? World J Hepatol. 2016;8:200–6.CrossRefPubMedPubMedCentral Barbosa M, Guardado J, Marinho C, et al. Cirrhotic cardiomyopathy: isn’t stress evaluation always required for the diagnosis? World J Hepatol. 2016;8:200–6.CrossRefPubMedPubMedCentral
Metadata
Title
Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom
Authors
Tetsuo Kon
Naoki Nakagawa
Fumitsugu Yoshikawa
Kazunao Haba
Nagako Kitagawa
Michihiro Izumi
Setsuo Kumazaki
Satoshi Ishida
Ryuichi Aikawa
Publication date
01-08-2016
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 4/2016
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-016-0664-5

Other articles of this Issue 4/2016

Clinical Journal of Gastroenterology 4/2016 Go to the issue